Format
Sort by

Send to

Choose Destination

Search results

Items: 3

1.

MEK inhibition enhances the response to tyrosine kinase inhibitors in acute myeloid leukemia.

Morales ML, Arenas A, Ortiz-Ruiz A, Leivas A, Rapado I, Rodríguez-García A, Castro N, Zagorac I, Quintela-Fandino M, Gómez-López G, Gallardo M, Ayala R, Linares M, Martínez-López J.

Sci Rep. 2019 Dec 9;9(1):18630. doi: 10.1038/s41598-019-54901-9.

2.

Protein Carbonylation in Patients with Myelodysplastic Syndrome: An Opportunity for Deferasirox Therapy.

Rodríguez-García A, Morales ML, Garrido-García V, García-Baquero I, Leivas A, Carreño-Tarragona G, Sánchez R, Arenas A, Cedena T, Ayala RM, Bautista JM, Martínez-López J, Linares M.

Antioxidants (Basel). 2019 Oct 24;8(11). pii: E508. doi: 10.3390/antiox8110508.

3.

Ruxolitinib in combination with prednisone and nilotinib exhibit synergistic effects in human cells lines and primary cells from myeloproliferative neoplasms.

Cortés AA, Diaz RA, Hernández-Campo P, Gorrochategui J, Primo D, Robles A, Morales ML, Ballesteros J, Rapado I, Gallardo M, Linares M, Martínez-López J.

Haematologica. 2019 May;104(5):937-946. doi: 10.3324/haematol.2018.201038. Epub 2018 Dec 13.

Supplemental Content

Loading ...
Support Center